– September 23rd through November 4th, 2021 –
SCCT WEBINAR SERIES:
WHY ATHEROSCLEROSIS IS ALL THAT REALLY MATTERS
Sponsored by Cleerly, Inc
This series of four one-hour webinars sponsored by Cleerly, Inc. will discuss how coronary atherosclerosis can be quantified and characterized using CCTA and how the results allow for more precise evaluation and treatment of patients with CAD.
Each session will include a 25-minute didactic lecture followed by a guided hands-on clinical case review. Each registrant will be given access to illustrative cases on the Cleerly platform and will be allowed to fully interact with each dataset using all available quantitative CCTA software tools.*
This series is co-hosted by American Society of Preventive Cardiology (ASPC). References to a specific product, process, or service by speakers in this webinar series do not constitute or imply an endorsement by the Society of Cardiovascular Computed Tomography or the American Society of Preventive Cardiology. The views and opinions expressed do not necessarily reflect those of the Society of Cardiovascular Computed Tomography or the American Society of Preventive Cardiology.
David Newby, MD, PhD
September 23, 2021 at 12 Noon ET
How Atherosclerosis Guides Diagnosis, Prognosis, and Clinical Decision Making to Improve Patient Outcomes
- CT appearance of different plaque types
- How they relate to prognosis
- How their quantification characterization can effect clinical decision making and outcomes
Matthew Budoff, MD, MSCCT
October 7th, 2021 at 12 Noon ET
CAD Tracking: Use of Serial CT with Atherosclerosis Quantification in Patient Management and Drug Discovery
- How plaques can be tracked on serial CT
- Define and give examples of progression, regression and stabilization
- Show how serial CAD disease tracking with CT can be used in patient management and has been used to demonstrate plaque changes over time with medication and other interventions
Michael Shapiro, MD, MCR, FSCCT
October 21st, 2021 at 11 AM ET
Use of Atherosclerosis Quantification with Medication, Diet, Activity and Education for Primary Prevention
- How the presence and quantity of atherosclerosis as depicted on quantitative CCTA can influence primary prevention beyond the use of traditional risk factors and ASCVD risk scores
- How it may affect compliance with medication and lifestyle changes
- The design and purpose of the new “ACC Treat Disease algorithms” (if in-print by late Oct)
Paul Knaapen, MD
November 4th, 2021 at 12 Noon ET
The Utility of Coronary Atherosclerosis Imaging to Guide Coronary Intervention
- How quantitative coronary plaque analysis can influence the decision to intervene
- How CCTA has been shown to successfully guide selective referral for ICA
- How to understand the 3D nature and composition of a plaque may guide how intervention is performed
Register Today!
Sign up on the SCCT website to receive access to the webinars and a free trial account of the Cleerly platform.
*Cleerly platform access is subject to sponsor approval. Registrations completed less than 72 hours prior to the event are not guaranteed to include access to the Cleery platform.
Upcoming Events Schedule
September 2021
September 23rd
12 Noon ET
David Newby, MD, PhD
How Atherosclerosis Guides Diagnosis, Prognosis, and Clinical Decision Making to Improve Patient Outcomes- CT appearance of different plaque types
- How they relate to prognosis
- How their quantification characterization can effect clinical decision making and outcomes
October 2021
October 7th
12 Noon ET
Matthew Budoff, MD, MSCCT
CAD Tracking: Use of Serial CT with Atherosclerosis Quantification in Patient Management and Drug Discovery- How plaques can be tracked on serial CT
- Define and give examples of progression, regression and stabilization
- Show how serial CAD disease tracking with CT can be used in patient management and has been used to demonstrate plaque changes over time with medication and other interventions
October 21st
11 AM ET
Michael Shapiro, MD, MCR, FSCCT
Use of Atherosclerosis Quantification with Medication, Diet, Activity and Education for Primary Prevention- How the presence and quantity of atherosclerosis as depicted on quantitative CCTA can influence primary prevention beyond the use of traditional risk factors and ASCVD risk scores
- How it may affect compliance with medication and lifestyle changes
- The design and purpose of the new “ACC Treat Disease algorithms” (if in-print by late Oct)
November 2021
November 4th
12 Noon ET
Paul Knaapen, MD
The Utility of Coronary Atherosclerosis Imaging to Guide Coronary Intervention- How quantitative coronary plaque analysis can influence the decision to intervene
- How CCTA has been shown to successfully guide selective referral for ICA
- How to understand the 3D nature and composition of a plaque may guide how intervention is performed